Search results
Results from the WOW.Com Content Network
Trastuzumab, a monoclonal antibody against HER2, added to chemotherapy, has been proven in clinical trials to extend the time to disease progression, increase response rates, prolong response duration, reduce the death rate at 1 year, improve overall survival, and lower the risk of death by 20%. This demonstrates trastuzumab's significant ...
As of 2019, pembrolizumab, which blocks PD-1, programmed cell death protein 1, has been used via intravenous infusion to treat inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain situations, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC), after platinum-based chemotherapy ...
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
Feelings of nausea occur among approximately 7 out of every 10 people (70%) but this can be well controlled with anti-nausea drugs. There are many options available to treat chemotherapy-induced nausea and vomiting. Pain in the vein during the infusion of oxaliplatin or folinic acid – This can be managed by decreasing the rate of infusion.
These micrometastases can be treated with adjuvant chemotherapy and can reduce relapse rates caused by these disseminated cells. [9] Maintenance chemotherapy is a repeated low-dose treatment to prolong remission. [5] [6]: 55–59
photo showing chemotherapy with chemo infusion. High-dose chemotherapy (HDC) is a regimen of chemotherapy medicines given at larger dosages. This therapeutic strategy is used to treat some cancers, especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body ...
With a minimum follow-up of 21.0 months, Opdivo with chemotherapy reduced the risk of disease recurrence, progression, or death by 37% across randomized patients when administer
The 6-year leukemia-free survival (LFS) and overall survival (OS) rates were 84.4% and 89.5%, respectively, in the low-risk group, which were similar to the rates in the intermediate-risk group (59.2% and 65.2%, respectively); The 6-year LFS and OS were 76.4% and 82.1%, respectively, in patients who received a high dose of donor CD3+ T cells ...